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Abstract
Background: Mesenchymal Stromal/Stem Cells (MSCs), isolated under the criteria established by the ISCT, still
have a poorly characterized phenotype that is difficult to distinguish from similar cell populations. Although
the field of transcriptomics and functional genomics has quickly grown in the last decade, a deep comparative
analysis of human MSCs expression profiles in a meaningful cellular context has not been yet performed. There
is also a need to find a well-defined MSCs gene-signature because many recent biomedical studies show that
key cellular interaction processes (i.e. inmuno-modulation, cellular cross-talk, cellular maintenance, differentiation,
epithelial-mesenchymal transition) are dependent on the mesenchymal stem cells within the stromal niche.
Results: In this work we define a core mesenchymal lineage signature of 489 genes based on a deep comparative
analysis of multiple transcriptomic expression data series that comprise: (i) MSCs of different tissue origins; (ii) MSCs in
different states of commitment; (iii) other related non-mesenchymal human cell types. The work integrates
several public datasets, as well as de-novo produced microarray and RNA-Seq datasets. The results present
tissue-specific signatures for adipose tissue, chorionic placenta, and bone marrow MSCs, as well as for dermal
fibroblasts; providing a better definition of the relationship between fibroblasts and MSCs. Finally, novel CD
marker patterns and cytokine-receptor profiles are unravelled, especially for BM-MSCs; with MCAM (CD146)
revealed as a prevalent marker in this subtype of MSCs.
Conclusions: The improved biomolecular characterization and the released genome-wide expression signatures of
human MSCs provide a comprehensive new resource that can drive further functional studies and redesigned cell
therapy applications.
Keywords: Stromal cells, Mesenchymal stem cells, Placenta, Bone marrow, Adipose tissue, Human gene
expression, Bioinformatic meta-analysis, Cytokines, CD marker
Background
Stromal cells are connective tissue cells that support
the functional part of an organ. The fibroblast (FIB) is
the prime representative of a stromal cell type. Mesen-
chymal stem cells are adult, self-renewing multipotent
progenitors that also inhabit the stromal compartment
[1–4]. A population of stromal cells that demonstrate
stem cell capabilities liable to be isolated from the bone
marrow and from other diverse human tissues (like
adipose, cartilage, muscle), is what we know as the
Mesenchymal Stromal/Stem Cell population (MSCs)
[5]. Specific traits that lead to the separation of uncom-
mitted stages from differentiated ones are not yet conclu-
sively deciphered. Nevertheless, the expanded settlement
along the body of MSCs, the easiness of in vitro culturing,
their differentiation capabilities, and their contained
immuno-modulatory capacities have empowered them to
be used in regenerative medicine for restoring the matrix
or cellular elements of damaged tissues or for diminishing
inflammatory or immune reactions. For these reasons,
the MSCs have been also included in many recent cell
therapy trials [6].
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Cellular phenotypes can be defined by the expression
and active contribution of specific genes. Therefore, many
genome-wide profiling studies have been undertaken to an-
swer unresolved questions over specific cell types. In the
case of human MSCs, differentially expressed genes have
been explored in pioneering studies by Wagner et al. [7]
using global gene expression profiling. Different probe
methodologies and discrepant experimental and analytic
protocols interfere in the comparison between separate re-
ports. However, as technology has been progressing, cell
gene signatures have improved in sensitivity and specificity.
To characterise the specific identity features of MSCs, we
took advantage of multiple accessible transcriptomic data
gathered from different cell types with different degree of
commitment. At the same time, we undertook a de-novo
study based on new experimental data, generated to investi-
gate the nature of MSCs and the inherent changes associ-
ated to their different tissue origins, variability that tissue-
MSCs retain even during the first culture expansion stages
[8, 9]. As a whole, the data collection produced to feed the
performed study included 264 samples selected from public
databases, a self-produced dataset of 15 samples analysed
with high-density exon microarrays, and an additional set
of six samples analysed with RNA deep-sequencing tech-
nology. The construction of a large transcriptomic frame-
work of human stromal cells, together with their most
related cell types, have facilitated to identify the relative dif-
ferences and similarities between them.
Analysing the global gene expression profiles with a
robust approach, we have been able to identify a
polished signature comprising the common MSC lineage
features in a set of 489 up-regulated genes. Functional
linkage among signature genes also established the basal
mesenchymal routines that cells normally trigger in their
lifetime. Specific genes associated to each tissue were
also scrutinised, specially the cytokine and the CD pat-
terns. We have further explored the transcriptome of the
bone marrow population of MSCs (BM-MSCs) and in-
vestigated the potential interactions with their niche-
mates, the hematopoietic stem and progenitor cells
(HSPCs). The exchanged signals and cross-talk interac-
tions between these two, determines the establishment
of the functional bone marrow microenvironment. Fi-
nally, by overlapping the results of our extensive data-
driven exploration with other published signatures in a
state-of-the-art compendium, we rescued genes that ap-
pear frequently reported, underlying the value of the
MSCs characterisation presented.
Results
Cytological variations of stromal cells from different
origins
Primary cultures of stromal cells isolated from different
origins included: MSCs from adipose tissue (AD-MSCs),
MSCs from bone marrow (BM-MSCs) and MSCs from
placental tissue (PL-MSCs); as well as fibroblasts (FIB)
from dermal tissue. Under the microscope, the fibroblas-
tic spindle-shape of stromal cells appeared clearly mani-
fest along the study cultures (Fig. 1a). Some peculiarities
in cell morphology may certainly be appreciated between
stromal cells from different tissue origins. The placental
MSCs were the longest, similar to fibroblasts. BM and
AD-MSCs were difficult to distinguish and had a more
irregular morphology in culture, with cells that mixed
fusiform shapes with less elongated star shapes.
In terms of cell growth rates, population-doubling
times were significantly shorter on fibroblasts, followed
by PL-MSCs and later AD- and BM-MSCs. Between
these last two, no significant differences were found.
Wilcoxon test p-values point out the differences in
growth rate between cultures (see boxplot and table in
Fig. 1b, c). The complete data collected from cultures is
available in Additional file 1.
The intensity of standard CD markers detected by flow
cytometry assays in different stromal cells is presented
in comparative boxplots in Fig. 1d. CD90 showed the
strongest signal and, strikingly, the highest in fibroblasts
and the lowest in PL-MSCs among the cellular classes.
CD90 together with CD44 resulted the most discrimin-
ating for FIBs from the rest of the MSC populations. Of
less variability resulted CD73, been similar to AD- and
BM-MSCs, and expressed stronger in PL-MSCs and
FIBs. CD105 showed similar expression along all cell
populations. Forward scatter and side scatter measures
also denoted differences (Fig. 1e). These cytometric pa-
rameters showed that fibroblasts are the smallest and
less internally complex cells.
The complete panel of cytological assays defined by
the ISCT confirmed the characteristic phenotype of mes-
enchymal stromal cells. Histograms of cytometry assays
for each sample type are supplied in Additional file 2.
Confirmatory microscopic snapshots of tri-lineage differ-
entiations of the three tissue-MSCs are also supplied in
Additional file 3. To address the transcriptomic study of
all these cell types, the produced and verified primary
cultures of stromal cells were used to generate an in-
house de-novo gene expression dataset.
Meta-analysis of multiple sample series of MSCs
and other related cell types
To begin the identification of human mesenchymal stro-
mal cells, we first searched in multiple public databases
to find a collection of datasets that could be assembled
and analysed in a common framework. In this way, we
integrated several transcriptomic data series and carried
out a meta-analysis study on them. We first explored the
genome-wide expression profiles to better visualise the
relationships of MSCs to differently related cell types:
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Fig. 1 (See legend on next page.)
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from same lineage derived osteoblasts, adipoblasts, chon-
droblast or fibroblasts, to lineage flipped hematopoietic
progenitors (HSPCs) and differentiated cells (e.g. lympho-
cytes), and cells from foetal origin.
The meta-analysis study approach allows increasing
the number of samples available, thus improving the
robustness of the results. In our case, a meta-set of 264
expression microarrays from 18 independent data series
were selected through a discriminating process that
included a total initial collection of more than 500 sam-
ples (Additional file 4). A benchmark of several bio-
logical backgrounds was created, including samples
from the mesenchymal lineage, together with samples from
the hematopoietic lineage. Cells from the hematopoietic
system presented a well-characterised immunophenotype
that defined each cellular population along the maturation
process. This brought a well-known system that served as
distant control group to compare the less phenotypically
characterised cells from the stromal lineage. Differentiated
cells of both lineages, even from unrelated tissues, were in-
cluded whenever available, to provide a broader profiling.
The transcriptomic profiles produced provide a view
of the relationships between cells, considering differ-
ences and similarities as distances or proximities that
the cells exhibit, associated to the functional back-
grounds they come from. A non-supervised hierarch-
ical clustering analysis of global expression, based on
Pearson correlations, is represented in the heatmap in
Fig. 2a. The heatmap shows that hematopoietic
(marked in red) and mesenchymal (marked in yellow)
lineages fall clearly separated in two main clusters.
Samples from foetal origin, included inside both line-
ages, are segregated from their other relatives. In this
way, the distribution of samples is primarily associated
to the cellular lineage, as well as their differentiation
state and tissue of origin. A very similar biologically
distributed clustering is preserved when performing a
principal component analysis (PCA). Information con-
tained in the principal components is exposed in
Fig. 2b and c. A 3D plot in Fig. 2b displays the distri-
bution of 264 samples within the space of the three
first components of the PCA using genes as variables.
The cumulative variance explained by these three
components is 33.28%, 45.75% and 56.11%. A mean-
ingful reading of these PCA results is the agreement
between the unsupervised clusterisation –based on the
whole genome expression– and the biological cell
types studied. The main variance accumulated in the
first PC primarily explains the cellular lineage vari-
ation. The second and third PCs further explain the
cell type specificity intrinsic to each lineage. Using
samples as variables, another PCA was done and the
cumulative variance explained by the first components
was: PC1 81.72%, PC1 + PC2 88.11% and PC1 + PC2 +
PC3 90.21%. The Biplot presented in Fig. 2c shows the
two principal components representing 88% of the
variability. Thus, PC1 and PC2 account for the main
separation between the two types of cellular lineages:
stromal cells in one part and hematopoietic cells in the
other. The coherence with biology of sample distribu-
tions also manifests that batch-effects are not relevant
in the data. Thus, the pre-processing and normalisa-
tion steps have been well accomplished, making the
collection suited for upcoming differential expression
comparisons and further integrative analysis (pre-
sented in the following sections of the Results).
Clustering and PCA analyses performed over the glo-
bal expression profiles show that the transcriptomes
appear associated by their biological context of origin,
with a clear segregation between the hematopoietic cell
lineage and the mesenchymal cell lineage, as well as
clear proximity of the different cell types assigned to the
mesenchymal lineage: adipoblasts, chondroblasts, fibro-
blasts and osteoblasts. An interesting result is the way
differentiated cells cluster with respect to the progenitor
cells. Lymphocytes get a position separated from their
hematopoietic progenitors. However, fibroblasts do not
appear very much segregated from other stromal cells in
this comparison, and mesenchymal samples gather
closer than the samples from hematopoietic cells. This
proximity occurs even considering that most of the
MSCs included here come from the bone marrow; how-
ever fibroblasts come from the dermis, two distant tis-
sues that do not seem to mark as important differences
in terms of whole gene expression as the distance ob-
served between the stromal and the hematopoietic
progenies.
With respect to the samples of foetal origin, in the
case of HSPCs there is a clear difference between the
foetal and adult origin, but in the case of MSCs the ex-
pression profiles are much less different (Fig. 2a). The
larger difference observed in the case of HSPCs should
(See figure on previous page.)
Fig. 1 Characterization of MSCs following the ISCT criteria. a Microscope photographs of human stromal cells in culture taken at passage three:
phase contrast micrographs seen at 4× and 10×. b-c Analysis of population doubling times: b boxplot of the doubling time distributions per
stromal cell culture; c Wilcoxon test results of contrasted doubling times between stromal types. (DT = Doubling Time; W = Wilcoxon Test;
CI = Confidence Interval). Labels for stromal cell types: AD = Adipose tissue MSC; BM = Bone marrow MSC; PL = Placental MSC; FIB = Dermal
fibroblasts. **Significant p-values under 0.05. d-e Boxplots of normalized scatter intensities collected from flow-cytometry immunophenotyping as-
says using 10 different markers: CD105, HLADR, CD19, CD45, CD166, CD14, CD73, CD90, CD44 and CD34. (SSC = side scatter; FSC = forward scatter)
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be expected, since it is known that human foetuses have
a different hematopoiesis to adults because prenatal
hematopoietic stem cells are formed in multiple anatom-
ical sites (faetal liver, placenta, etc.), and they only colon-
ise the bone marrow at birth to establish a normal
hematopoiesis during postnatal life. In this way also, the
lymphocytes and the immune system are still not fully
developed in the embryonic stages and foetal erythro-
cytes express several specific proteins, like “foetal
haemoglobin”, that are not present in adult blood.
Transcriptomic homology between MSCs from different
tissue origins, FIB and HSPCs
Since the first descriptions of MSCs in the bone marrow
[1, 10], many tissues have been disclosed as sources of
MSCs: muscle, skin, adipose tissue, umbilical cord blood,
Wharton’s jelly, placenta, etc. We focused the following
analyses to the characteristics that the different tissue
basements confer to MSCs. We produced an in-house
genome-wide expression dataset with MSCs from three
different tissue origins. The platform Affymetrix Human
Exon 1.0 was used since it allowed the expansion of the
range of gene loci assayed from ~17 k (in older Affyme-
trix platforms included in the meta-analysis) to ~20 k
genes.
Cultured populations of MSCs from adipose tissue
(AD), bone marrow (BM) and placenta (PL) were sub-
mitted to genome-wide expression profiling, together
with skin fibroblasts (FIB) and HSPCs as contrast cell
types. As shown in the preceding results, fibroblasts
present a close relationship to the populations of MSCs
and the rest of the stromal lineage cells. On the other
hand, HSPCs provide a different lineage contrast related
to stem cells, but not to the mesenchymal lineage.
Principal component analysis of the 15 samples
(Fig. 3a) reproduced the behaviour observed in the
meta-analysis: clear segregation of HSPCs from the mes-
enchymal lineage, and close association of fibroblasts to
Fig. 2 Meta-analysis of MSCs and related cell types. a Sample-to-sample heatmap of 264 microarrays that includes mesenchymal and hematopoietic
lineage cells. Clustering of samples relies upon Euclidean distances derived from the pairwise calculation of the Pearson correlation between
the expression vectors of each sample. In the right panel: the hematopoietic lineage samples are shaded in red and mesenchymal lineage
samples are in yellow. The colour scale represents shorter to larger distance: from dark red to dark blue. b 3D plot of PCA based on the gene
expression of the stromal and hematopoietic cells studied. Each dot represents a sample microarray from the repertoire of 264 and includes the
global gene expression for each sample. c Biplot of PCA performed by genes of the same data. Samples are represented as arrow vectors in
the derived PCA space on the Biplot
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the rest of the MSCs from the three different tissues.
The cumulative variance explained by the 3 components
here represented was: 33.61, 50.76 and 58.62%. In
addition, another PCA including only MSCs and fibro-
blasts reveals a clearer separation of the cell types, show-
ing the fibroblasts in a most-compacted cluster with less
sample-to-sample variability than the rest of the MSCs
(Fig. 3b). The cumulative variance explained in this case
was: PC1 33.93%, PC1 + PC2 46.12% and PC1 + PC2 +
PC3 56.27%.
To observe the system through a narrower window,
we performed a semi-supervised clustering analysis con-
sidering only the collection of 358 CD genes, defined as
clusters of differentiation targetable for cell immunophe-
notyping (Fig. 3c). These known cell surface marker pro-
teins allow the display of cell relationships focusing on
the currently available phenotypical knowledge. The cor-
responding dendrogram in the upper margin of the heat-
map (Fig. 3c) shows that the cellular entities were well
segregated, the replicates were not mixed with each
other, whilst the three subtypes of tissue-MSCs were
closely clustered. Interestingly, BM-MSCs and not fibro-
blasts are the first population more separated within the
stromal repertoire when CD markers are used for sam-
ple clustering. Analysis of the samples clustering based
on all-genes (i.e. unsupervised clustering of samples
based on Pearson correlations of the expression along all
genes) indicates that BM-MSCs are within the tissue-
MSCs cluster (Additional file 5). These broad clustering
analyses based on the whole genome-wide expression
profiles show only the main trends, but deeper analysis
of the specific genes activated in each cell type and
Fig. 3 Analysis of tissue-MSCs in a de-novo dataset of 15 microarrays. a 3D plot of PCA performed for samples of all the cells under study (15 ar-
rays) using the whole gene expression profiles. b 3D plot of PCA performed only with the stromal cell samples (12 arrays) removing the
hematopoietic cells. c Heatmap of semi-supervised clustering based on the 358 CD marker genes. (The expression scale is in log2-transformed
intensity values. The microarrays platform used was:Affymetrix Human Exon 1.0)
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subtype should be performed to achieve better definition
of stromal cells phenotype and understand their similar-
ities to other cells.
Differential expression (DE) signatures that define tissue
specificity of MSCs
Going further within the transcriptomic profiling and as
a way to evaluate the similarity between MSCs, we tackle
the idea of establishing the number of differentially
expressed (DE) genes as a measurable value of cell popu-
lation distances. First, we present the results derived
from the meta-analysis of 119 samples obtained from 16
different published datasets, that included a collection of
50 BM-MSC samples (Additional file 4). These analyses
were done using a re-sampling method (as indicated in
Methods) that allows finding the most stable differential
expression gene signatures. Three main contrasts were
designed to compare BM-MSCs against other cell types:
(1) BM-MSCs versus HSPCs, (2) BM-MSCs versus skin
Fibroblasts, and (3) BM-MSCs versus Osteoblasts. A
summary describing all these comparisons and the DE
outcomes is included in Additional file 6. This approach
yielded a value of 401 DE genes between BM-MSCs and
FIB, with 207 up-regulated and 194 down-regulated in
BM-MSC. The contrast between BM-MSCs and HSPCs
yielded 4748 DE genes (2124 up-regulated and 2624 and
down-regulated, in BM-MSC). As expected, broadly
used MSC markers CD73 (NT5E), CD90 (THY1) and
CD105 (ENG, Endoglin) were found up-regulated along
the listed genes. Table 1 presents 28 CD marker genes
found in the complete list of significant genes. When we
crossed lists of up-regulated genes in BM-MSCs from
both contrasts (versus FIBs and versus HSPCs), one CD
marker gene (i.e. CD146) and two transcription factors
(i.e. ID3 and PAWR) remained in the intersection. The
MCAM glycoprotein gene (CD146) has been postulated as
a marker of MSCs population in the sub-endothelial niche
within the bone marrow [11, 12].
To better prove the value of the differential expres-
sion signatures obtained, we used again the re-sampling
tool to perform exploratory tests upon some training
samples of the microarray collection. Unrelated mesen-
chymal samples following osteogenic induction, either
in vivo or using certain effector molecules, were sub-
mitted to the re-sampling process (see Additional file 6
contrasts 3, 4A, 4B and 4C; and plots in Additional file 7).
These re-sampling analyses yielded inconsistent numbers
of differentially expressed genes between conditions,
with no significant outcome in some cases (e.g. contrast
4C). Such anomalous results could be due to the com-
parison of very similar cell types –that would not have
any significant gene change– or the comparison of very
heterogeneous and disperse cellular states. The heterogen-
eity could come from stochastic responses to the different
stimulus that were applied to the stromal cells studied
(see, for example, differential expression re-sampling
curves in contrast 4A: BM-MSC versus dOST; and in con-
trast 4C: OSTB versus stOSTB) (Additional file 7). These
results prove the high sensitivity of the method to sample
alterations, and, thus, the robustness to find the most
stable genes in each differential expression contrast. This
stability also adds value to the signatures obtained by re-
sampling, i.e. the ones produced in the first and second
contrasts (contrasts 1 and 2, Additional file 7).
An enrichment analysis directed to explore the func-
tional and biological meaning of the differentially
expressed genes in MSCs is included in Table 2. When
compared to HSPCs, certain functions are enriched in
the BM-MSCs gene signature: blood vessel development,
vesicle localisation, cell migration, cell death regulation.
Moreover, hematopoiesis and leukocyte activation pro-
cesses are enriched in HSPC genes. Significantly, in the
comparison with fibroblasts, more BM-MSC genes ap-
pear annotated to bone development tasks (e.g. skeletal
system development) and skeletal fibre organisation (e.g.
Z disc and myofibril). By contrast, fibroblasts showed a
clear enrichment in genes related to the organisation
and function of the extracellular matrix.
Differential expression (DE) analyses were also per-
formed in our in-house controlled dataset, which in-
cludes MSCs from three different sources. Figure 4a
and b show two red-green heatmaps where the inten-
sity increases proportionally to the number of DE genes
between each contrast performed. The upper panel
(Fig. 4a) includes the HSPCs, that are removed in the
lower panel (Fig. 4b) to strengthen the comparisons be-
tween stromal cell types. In this comparison, the stron-
gest differences were observed between PL-MSCs
against all other stromal cells. This result may reflect
the foetal nature of the placental cells. The opposite oc-
curs for AD-MSCs, which show the lowest number of
DE genes. This may indicate that this cell subtype in
the adipose niche needs to prompt fewer specific genes
to perform their tissue-specialised tasks.
The exact number of DE genes for all the pair-wise
comparisons are presented in three tables in Fig. 4c, d, e.
An additional contrast class, formed by the three tissue
MSC samples, is also included in these analyses. This
‘all-MSCs’ class shows 5,919 DE genes against HSPC,
but only 136 DE genes against FIB. These numbers may
be considered a distance measurement between the cel-
lular entities studied. Such values are similar and pro-
portional to the measures obtained in the meta-analysis
of public datasets, strengthening the reliability of our
biological observations.
The described results bring forward the question of
which genes might be specifically associated to each tis-
sue origin of the MSCs analysed. To withdraw the
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potential tissue specific genes, we extracted the common
DE genes of each MSC class across different compari-
sons. Intersections of DE gene lists are presented in
Venn diagrams in Fig. 4f, where we only include the
genes that were up-regulated in the comparisons of the
indicated cell type with the others, for example for
AD-MSCs: 181 genes versus PL-MSCs, 64 genes versus
PL-MSCs and 102 genes versus FIB. From all these in-
tersections we observed that, proportional to DE values,
PL-MSCs present the largest list of tissue specific genes
and AD-MSCs the shortest: 123 and 9, respectively, differ-
entially expressed in all the comparisons against the rest
of stromal cells. These genes encountered in the intersec-
tions will be very specific to each tissue-MSC. The lists
corresponding to these genes are provided in Table 3.
Some genes found are: VCAM1 (CD106) in BM-MSCs;
NCAM1 (CD56) and DNAM1 (CD226) in PL-MSCs;
PPAPDC1A in AD-MSCs (i.e. phosphatidate phosphatase
involved in fatty acid metabolism); TWIST1 and TWIST2
in FIB (known as mesodermal determinant factors that
block bone specification fate) [13].
Correspondence or overlapping between DE gene sets
obtained from the two approaches presented (i.e. the
meta-analysis set derived from public data series and
Table 1 CD marker signature defined for BM-MSCs
CD identifier Gene aliases Description
CD13 ANPEP; PEPN Aminopeptidase N (Microsomal aminopeptidase) (Gp150)
CD49c ITGA3 Integrin alpha-3 (Integrin VLA-3 alpha subunit) (Galactoprotein b3)
CD49e ITGA5; FNRA Integrin alpha-5 (Integrin VLA-5 alpha subunit) (Fibronectin receptor alpha subunit)
CD58 CD58; LFA3 Lymphocyte function-associated antigen 3 (Surface glycoprotein LFA-3)
CD63 CD63; MLA1 CD63 antigen (Melanoma-associated antigen ME491) (LAMP-3) (Ocular melanoma-associated antigen)
(OMA81H) (Granulophysin) (Tetraspanin-30)
CD73 NT5E; NT5; NTE 5′-nucleotidase
CD90 THY1 Thy-1 membrane glycoprotein
CD105 ENG; END Endoglin
CD107a LAMP1 Lysosome-associated membrane glycoprotein 1 (LAMP-1)
CD107b LAMP2 Lysosome-associated membrane glycoprotein 1 (LAMP-2)
CD140b PDGFRB Beta-type platelet-derived growth factor receptor (PDGF-R-beta)
CD146 MCAM; MUC18; CD146 Cell surface glycoprotein MUC18 (Melanoma cell adhesion molecule)
(Melanoma-associated antigen A32) (S-endo 1 endothelial-associated antigen)
(Cell surface glycoprotein P1H12)
CD147 BSG Basigin (Leukocyte activation antigen M6) (Collagenase stimulatory factor)
CD156c ADAM10; MADM ADAM 10 (A disintegrin and metalloproteinase domain 10)
CD164 CD164 Putative mucin core protein 24 (Multi-glycosylated core protein 24)
CD167b DDR2; NTRKR3 Discoidin domain-containing receptor 2 (Tyrosine-protein kinase TYRO 10) (Neurotrophic tyrosine kinase,
receptor-related 3)
CD213a1 IL13RA1; IL13RA Interleukin-13 receptor alpha-1 chain
CD222 IGF2R; MPRI Cation-independent mannose-6-phosphate receptor (Insulin-like growth factor II receptor)
CD230 PRNP Major prion protein (PrP) (PrP27-30) (PrP33-35C) (ASCR)
CD248 CD248; TEM1 Endosialin (Tumour endothelial marker 1)
CD266 TNFRSF12A; FN14 Tumour necrosis factor receptor superfamily member 12A (Fibroblast growth factor-inducible
immediate-early response protein 14) (Tweak-receptor)
CD280 MRC2; ENDO180 Macrophage mannose receptor 2 (Urokinase receptor-associated protein) (Endocytic receptor 180)
CD284 TLR4 Toll-like receptor 4
CD292 BMPR1A; ACVRLK3 Bone morphogenetic protein receptor type IA (Serine/threonine-protein kinase receptor R5) (SKR5)
(Activin receptor-like kinase 3) (ALK-3)
CD304 NRP1; NRP Neuropilin-1 (Vascular endothelial cell growth factor 165 receptor)
CD317 BST2 Bone marrow stromal antigen 2 (BST-2)
CD331 FGFR1; FGFBR Basic fibroblast growth factor receptor 1 (bFGF-R) (Fms-like tyrosine kinase 2)
CDw210b IL10RB; CRFB4 Interleukin-10 receptor beta chain (IL-10R2) (Cytokine receptor class-II member 4)
Bold font indicates CDs previously reported or used as markers for BM-MSCs (update taken from Calloni’s et al. review [21])
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Table 2 Functional enrichment analysis of DE genes obtained from the meta-analysis approach








SEPT5, TGOLN2, SEC31A, FSTL3, ITSN1, C14ORF1, APP, BDNF, DAB2, PICALM, SCAMP1, BSG,
MYO6, ACTN1, OPTN, SSPN, SPAG9, VEGFC, SERPINF1, RAB14, TRAPPC4, PDCD6IP, COPZ2,
CAV2, RAB7A, PAM, COPZ1, ATP6V1B2, ITGB1, CALU, TIMP1, STX12, SLC30A5, TMED10, FN1,
AP2M1, PLAT, P4HB, BECN1, GARS, WIPI1, DVL1, LAMP1, LAMP2, PPIB, YIPF3, YIPF5, HSP90AB1,
COPA, CLTA, CLTB, SEC24A, RAB5B, AP2S1, HEXB, AP3S1, GJA1, PDIA6, PDIA4, CLTC, CANX,
RABAC1, SLC1A5, COPB2, AP2B1, TPP1, MAPKAP1, GOPC, GOLGA5, ATP6V0D1, SEC24D, STX6,
SEC23A, ADAM10, STX2, PIK3C2A, STXBP1, TMEM187, BGN, IGF2R, ARCN1, RAB5A, SORT1, CTSD,
CTSB, COPG, COPE, GANAB, ANXA6, CD9, TMED2, CRISPLD2, TMEM33, CAMK2D, RAB11A,
SNAP23, GPNMB, THBS1, EHD1, THBS2, EHD3, HSPA8, THBS3, PHLDA1, YWHAB, SPARC,




SEPT5, BBS4, COPA, MAP2K1, BBS7, COPZ1, WIPI1, COPB2, ARF1, PSEN1, ARCN1, TMED10,




RTN4, NRP1, HTATIP2, PGF, PRRX1, ANPEP, MMP2, CXCL12, CITED2, MAP3K7, AKT1, SHB,
ATG5, CTGF, ANG, ROBO1, SEMA3C, RHOB, LOX, NR2F2, FGF2, CYR61, RECK, MYH9, SLIT2,
THY1, VEGFC, BGN, HIF1A, NUS1, PSEN1, COL1A2, FOXC1, COL1A1, ACVR1, CAV1, TNFRSF12A,
COL3A1, CDH2, TCF7L2, SEMA5A, PTK2, ITGAV, CHM, THBS1, PPAP2B, C1GALT1, RASA1, PLAT,
EPAS1, MYO1E, TGFBR2, COL5A1, ANXA2, CDH13, GPI, LAMA4, PKNOX1, ENG, PLAU
60 3.02 5.06E-06
apoptosis DLC1, TSPO, HRAS, MEF2A, SGMS1, ITSN1, MAGED1, SHB, CLPTM1L, APP, CDKN2A, RAD21,
ATG5, UNC5B, GATA6, FAS, DAP, CUL1, CIB1, TWIST1, FADD, LIG4, BCAP31, PDCD6IP, NEK6,
BLCAP, TNFRSF12A, RRAGA, BCL2L2, STK17A, RRAGC, PEA15, PRUNE2, DOCK1, TCTN3, ABR,
TM2D1, LGALS1, SRA1, TRIO, FXR1, VDAC1, NCKAP1, BFAR, VCP, RABEP1, RTN4, HTATIP2,
SGPP1, ZMAT3, BNIP3, GJA1, PAWR, DAXX, RTN3, AKT1, TNFRSF11B, DYNLL1, PAK2, BOK,
GSN, BAG3, BAG2, RHOB, FGF2, MYC, MAGEH1, NDUFS1, DHCR24, LTBR, NOL3, ARHGEF12,
CDK5, ECT2, ELMO2, ZDHHC16, EYA2, PSEN1, AVEN, PSME3, UBE2Z, ITM2B, GLRX2, TNFRSF1A,
BCAP29, THBS1, PHLDA3, PHLDA2, ERCC2, PHLDA1, ACTC1, IL6, DNM1L, TMBIM6, UBE4B,
YWHAB, BAD, STAT1, PLEKHF1, NCSTN, BNIP3L, SULF1, PERP
103 5.18 2.75E-03
cell migration CTHRC1, JUB, NRP1, CXCL12, CTGF, ANG, ROBO1, SEMA3C, CAP1, NR2F2, FGF2, TWIST1,
PRKCA, PTPRK, SATB2, ARID5B, EMX2, NRD1, MYH9, CDK5, SLIT2, VEGFC, HIF1A, TNS1,
PSEN1, CFL1, SIX1, PDGFRB, FOXC1, LAMC1, ACVR1, CAV2, CCL2, NDN, FUT8, TNFRSF12A,
ITGA11, KITLG, CDH2, ITGB1, VCAM1, PTK2, PAFAH1B1, PPAP2A, THBS1, PPAP2B, APC,
FN1, PLAT, IL6, MET, COL5A1, CDH13, FYN, ITGA5, LRP6, APBB2, ENG, PLAU, MYH10
60 3.02 2.36E-04
Enriched functions in 2624 genes overexpressed in HSPCs compared to BM-MSCs
regulation of
leukocyte activation
LST1, HMGB3, BLM, STAT5A, IL18, SNCA, SPINK5, SART1, CD74, ADA, IL31RA, IL1B, MS4A2,
IL2RG, INPP5D, HLA-DOA, TRAF6, LAG3, CD28, SYK, FCER1A, PTPRC, IL2RA, GIMAP5, IKZF1,
FLT3, SLA2, CTLA4, STXBP2, IDO1, NFAM1, PRKCQ, CD38, CD83, CORO1A, CD86, TNFSF13B,
LAX1, PRAM1, RIPK2, IRF4, VSIG4, SASH3
43 1.92 9.33E-04
hemopoiesis LMO2, STAT5A, JAG2, TPD52, IL31RA, CDC42, SYK, RHOH, MB, EGR1, TTC7A, LYN, EOMES,
NFAM1, DHRS2, CD40LG, AICDA, ADD2, CALCR, GPR183, BLM, KIT, ZBTB16, SOX6, TRIM10,
CD74, ADA, TAL1, DOCK2, CHD7, RASGRP4, BCL2, BCL11A, TRAF6, CD28, PTPRC, GIMAP5,




of T cell activation
PTPRC, IL2RA, GIMAP5, IKZF1, BLM, STAT5A, IL18, ADA, CD74, SART1, CD83, PRKCQ,
CORO1A, CD86, TNFSF13B, RIPK2, IL1B, IL2RG, TRAF6, SASH3, CD28, SYK
22 0.98 2.44E-02
Enriched functions in 194 genes overexpressed in skin fibroblasts compared to BM-MSCs
extracellular matrix EGFL6, LGALS1, MMP27, GRIA3, EMILIN2, MMP3, NTN1, MMP1, WNT2, FBLN2, FBLN5, F3,
FBN2, MFAP4
14 7.57 5.22E-03
calcium ion binding S100A4, F10, MASP1, LDLR, EGFL6, SCUBE2, MMP27, COLEC12, GALNTL1, MMP3, SLIT2,
MMP1, DCHS1, STAT2, NPTX1, FBLN2, SVIL, FBLN5, ANXA11, CCBE1, FBN2, MFAP4, GALNT14
23 12.43 2.06E-02
EGF-like, type3 F10, LDLR, EGFL6, SCUBE2, FBLN2, FBLN5, CCBE1, ADAM33, FBN2, SLIT2 10 5.41 1.44E-02
Enriched functions in 207 genes overexpressed in BM-MSCs compared to skin fibroblasts
system development INHBA, RBP4, CTGF, DLX5, CHST11, FHL2, SORT1, MGP, FOXC1, NPR3, COL5A2, ANKH 12 6.32 5.08E-01
Z disc SORBS2, PDLIM5, DMD, FHL2, HOMER1 5 2.63 2.77E-01
myofibril SORBS2, PDLIM5, DMD, FHL2, HOMER1, TPM1 6 3.16 2.24E-01
Annotation Term: name and identifier of the annotated term in a functional database. Hits: (Observed Hits) number of genes from the DE gene list in each specific
annotation term. Adj.p-val: (Adjusted p-values) p-values from functional enrichment analysis were adjusted using the Benjamini and Hochberg method. Gene
symbols: identifiers of genes asigned to each functional term. Analyses were performed using DAVID web tool
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our de-novo set), reaches a percentage of 47% for up-
regulated genes in BM-MSC against HSPC.
Cytokine-receptor mapping based on expression patterns
Tissue-repair processes mediated by MSCs has been
proven in many cases as an effect of secreted growth
factors, cytokines, and other signalling molecules
[14]. Cytokines have the capacity to trigger the sig-
nalling cascades from cell-to-cell within a tissue. The
data presented in this work allow us to study the ex-
pression patterns of cytokines along populations of
tissue-MSCs.
Fig. 4 Differential expression analysis from the de-novo study of 15 microarrays. a Heatmap of distances measured as the number of differentially
expressed genes between each cell type. Red scale accounts for up-regulated genes in the cell type labelled in the right panel; whilst green
intensities represent down-regulated genes. The more intense the colour, the greater the distance between cell types involved. b Same as a,
but HSPCs were removed to improve the visualisation of the differences between stromal cell types. c-d-e Tables presenting the number of
differentially expressed genes per pair-wise comparison, indicating the up-regulated genes in each type (e.g. in d, BM-MSC versus PL-MSC:
346 genes UP in BM and 392 in PL). f Venn diagrams showing the number of genes that are up-regulated in each contrast against: AD-MSC
(green), BM-MSC (red), PL-MSC (blue) and FIB (yellow)
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Within the bone marrow niche, cytokines forge the
interactions within the two major inhabiting stem cell
populations: hematopoietic and stromal. Using our
meta-analysis data frame, we have looked for cytokines
among the genes up-regulated in BM-MSCs and in
HSPCs, and mapped them over the cytokine to
cytokine-receptor interactions (defined by KEGG). In
Fig. 5a, several mesenchymal-to-hematopoietic crossed
interactions from the KEGG pathway have been repre-
sented (whole mapping is included in Additional file 8).
The search across the meta-analysis dataset yielded 28
cytokine genes among 2,124 BM-MSC up-regulated genes
(hypergeometric enrichment p-value = 0.0099). Within the
same dataset, 52 cytokines were found among 2,624 HSPC
up-regulated genes (hypergeometric enrichment p-value
= 4.56 × 10e-09). Interestingly, HSPCs showed expression
of a greater bunch of cytokines than MSCs, which were
named cytokine ‘drugstores’ [15]. Previously described
critical interaction pairs, like CXCL12–CXCR4 or
KITLG–KIT, were present in our interaction map.
From the set of 28 BM-MSC cytokines found in the
meta-analysis, 11 appeared also differentially expressed
in the comparison of BM-MSCs versus HSPCs in our
de-novo study. These cytokines are: ACVR1, BMPR1A,
BMPR2, CCL2, IL13RA1, OSMR, PDGFRB, TGFBR2,
TNFRSF11B, TNFRSF12A and VEGFC.
Going further, we wanted to identify the potentially
tissue-specific cytokines of each stromal cell subtype.
We applied a hierarchical semi-supervised clustering
analysis over the cytokine panel using the expression
profiles of the 12 stromal samples from the de-novo
dataset. Figure 5b accounts for the 50% most variable
cytokines across all sample classes. Clusters showing
predominant expression in just one class of stromal
cells, according to their tissue of origin, have been
highlighted. For the bone marrow, cytokines CXCL16
and LEPR lead the profile of a 7-gene cluster. Associated
to the placental tissue, the cytokine pattern highlights
TNFSF4, 15 and 18, and PDGFC. Finally, KIT and BMP2
genes resulted over-expressed factors in the skin-derived
fibroblasts.
Mesenchymal lineage expression core signature
The hematopoietic cellular element (HSPCs), present in
both transcriptomic datasets studied, is the common
non-mesenchymal element of the cellular populations
analysed. We have used this out-of-lineage population as
contrast group to generate a mesenchymal lineage ex-
pression signature. Genes found up-regulated in each
comparison of the tissue-MSCs (AD, BM and PL)
against the HSPC set were matched together (see Venn
diagram in Fig. 6a). Common genes up-regulated in all
MSCs versus HSPCs were selected, obtaining 1,303
shared by the three tissue-MSCs included whithin the
in-house dataset. From this signature, 489 genes over-
lapped with the BM-MSC up-regulated genes from the
meta-analysis and with the previously characterised
MSC gene footprint defined by our group using RNA-
Seq [16]. Therefore, we can consider this set of 489
genes as the most conservative core of differentially
expressed genes in MSCs, i.e. the genes that compose a
well defined “mesenchymal lineage expression signature”
(the complete list is included in Additional file 9).
Table 3 Tissue specific gene signatures: list of genes appearing differentially expressed in each tissue-MSC and fibroblasts when






AD-MSC 9 AC104654.2, AP000695.2, AP000843.1, MATN3, MFAP3L, PCDH9, PDLIM3, PPAPDC1A, Z69713.1
BM-MSC 37 ACAN, AGT, ANK3, AP001422.1, C20orf103, C20orf197, C5orf23, CHRDL1, CXCL16, DLX5, ENTPD1, EPHX1,
EYA1, EYA2, EYA4, FBXO16, FMO3, HEY2, IGF2, IGFBP2, ITGA7, JAG1, KCNMB1, KIAA1217, KLHL3, LBP, LEPR,
MAOB, NOTCH3, NPR3, RP11-145A3.3, SFTA1P, SLPI, TM4SF20, VCAM1 (CD106), ZNF423
PL-MSC 123 AC003092.2, AC012409.1, AC026250.2, AC069155.1, AC090625.2, ADAM23, ADRA1D, AL121578.3, ALDH1A1,
ALDH1A2, AMIGO2, ANO4, AR, ATRNL1, BRIP1, C10orf57, C12orf59, C16orf52, C3orf72, C9orf167, CACNA1H,
CADPS2, CAMK1G, CAPN6, CARD16, CKS2, CNTN4, CTSH, CYTSB, DGKH, DNAM1 (CD226), DTNA, E2F7, ETV4,
F2RL1, FABP4, FAM105A, FAM155A, FAM60A, FJX1, GAS2L3, GBP4, GCLC, GLRXP3, GPR126, GPR37, HMGA2,
HOXD10, HSD17B2, HTR1D, HTR2B, IFIT2, IFIT3, INA, KCNA3, KRT19, LAMA1, LCP1, LIMS1, LPCAT2, LRRC1,
MAP3K5, MAPK8, MCTP1, MSI2, MUM1L1, NCAM1 (CD56), NEFM, NETO2, NID1, NNAT, NR2F1, PAMR1, PCDH10,
PDCD1LG2, PDGFC, PLAT, PLBD1, PLCXD3, PMAIP1, RARB, RASGRP1, REN, RP11-117P22.1, RP11-251 J8.1,
RP11-332P22.1, RP11-548O1.1, RP11-87H9.2, RP4-706A16.2, RPS6KA6, S1PR3, SCN9A, SERPINB2, SGIP1, SLC16A4,
SLC1A2, SLC4A8, SLITRK4, SNCA, SNCAIP, SNORD27, SOCS1, SORBS1, SOX5, SSTR1, ST6GALNAC5, STRA6, SYPL2,
SYT14, SYT16, SYTL5, TFPI2, TMEM154, TMEM51, TNFSF15, TNFSF18, TNFSF4, TRHDE, TRPC4,
ZNF516, ZNF804A
FIB 60 AC008440.2, AC112217.2, ADAM33, ADH1B, AIM1, AK5, APCDD1, APOD, AQP9, BMPER, C9orf21, CCBE1,
CCDC102B, CCRL1, CDON, CH25H, CLIC2, COLEC12, CYP7B1, DKK2, DNM1, GLDN, GLI3, GRPR, GTSF1, IGSF10,
KIAA0802, KIT, LRRC15, MASP1, MBNL3, MMP27, OMD, OR1H1P, OR1Q1, OSR2, PAX3, PDGFRL, PHACTR3, PLEKHG1,
PLXNC1, PRLR, RCAN2, ROBO2, RP11-392O17.1, RXFP1, SECTM1, SEMA3D, SIPA1L2, SLC9A9, STK32B, SVIL, TDO2,
TFAP2C, TGFBR3, THBS4, THRB, TWIST1, TWIST2
Gene symbols in bold correspond to relevant genes that are commented in the discussion
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As significant elements that support the value of the
signature, we can highlight some of the mesenchymal
specific genes included in it: stromal standard bio-
markers THY1 (CD90) and NT5E (CD73), transcription
factor SNAI2 (that is an epithelial-mesenchymal transi-
tion regulator), several collagen molecules involved in
the stroma (COL3A1, COL4A1, COL4A2, COL5A1,
COL5A2, COL6A3, COL12A1), and the BMP receptors
(BMPR1A, BMPR2) involved in the differentiation and
specification of mesenchymal precursor cells. Moreover,
together with SNAI2, this MSC lineage signature in-
cludes 12 other transcription factor genes: ARID5B,
CREB3, EPAS1, FHL2, GTF2E2, GTF2IRD1, ID3,
LMO7, TAF13, TEAD3, TULP3, and ZNF532.
Biological processes prompted by these 489 genes were
unravelled applying functional enrichment analysis tools.
The GeneTerm-Linker functional analysis tool provided a
non-redundant clustering of biological terms to which
the signature genes were annotated. The table in Fig. 6b
shows a summary of the results (the complete table is
found in Additional file 10). Nine clusters of enriched
biological terms and functions (called metagroups and la-
belled as MG) were found. Significantly, functions related
to BMP signalling, osteoblast differentiation, mesoderm
formation, collagen fibril organization and extracellular
matrix structure, appeared among the biological enriched
annotations.
To validate the generated MSCs signature, we per-
formed another principal component analysis over our
de-novo produced dataset of 15 microarrays (9 tissue-
MSCs, 3 HSPCs and 3 Fibroblasts) using only the 489
genes included in the mesenchymal lineage expression
core signature (results presented in Additional file 11).
The outcome of this PCA shows a cumulative variance
Fig. 5 Cytokine expression patterns of MSCs. a Cytokine interactions between BM-MSCs and HSPCs. Differentially expressed cytokines in BM-MSCs
(yellow) and HPCs (red) were coloured over the interaction map, highlighting the potential interactions established between the two cell types in
the bone marrow. A complete mapping over the cytokines KEGG pathway can be seen on Additional file 8. b Heatmap clustering of microarrays
samples based on the cytokinome intensity patterns. A gene cluster has been selected per stromal cell class. Stars denote double positive cyto-
kines also found in the intersection of the corresponding differential expression contrasts
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Fig. 6 (See legend on next page.)
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explained by the genes in the first 3 components of: PC1
78.79%, PC2 91.76%, PC3 94.20% (using the samples as
variables and represented as a Biplot in Additional file
11 A); and a cumulative variance explained by the sam-
ples in the first 3 components of: PC1 84.04%, PC2
88.51%, PC3 91.91% (using the genes as variables and
represented as a 3D plot in Additional file 11 B). These two
figures show that the separation between hematopoietic
and mesenchymal lineages is more strongly marked com-
pared to the previous PCA done with the whole transcrip-
tomic signal using the 264 meta-analysis microarray dataset
(Fig. 2b and c). The plots also show that the PCA based on
the 489 genes of the MSCs signature provides much better
separation between the cell subtypes than the PCA based
on the whole gene expression signal of the 15 exon
microarray samples of this study (Fig. 3a and b). Clus-
ters are better defined now, and PC3 allows an evident
separation of the stromal cell samples, including a
91.9% explained cumulative variance. Moreover, the
fibroblast samples come apart in a cluster separated
from the tissue-MSC samples. This is an interesting
new perspective, considering that the analyses previ-
ously performed with the whole transcriptome in differ-
ent sample sets were not able to provide such clear
segregation.
MSCs functional gene network
We built a functional network founded on the
metagroups recruited from the enrichment analysis
(Fig. 6b, c) for better analysis and visualisation of the
meaningful associations between the 489 MSC genes.
Genes are linked to the metagroups in which they are
annotated; in other words, the graph displays clusters of
genes sharing similar biological annotations and func-
tional roles [17]. Genes (circular nodes) linked by edges
to metagroups (squared nodes) reflect the membership
to a specific functional group and show the sharing of
common biological roles with other genes. In this bipart-
ite network, the metagroups act as hubs denoting inte-
grative roles within the mesenchymal core signature.
Some metagroups can share many genes with others,
but other metagroups are more exclusive. In this way, a
general overview of this functional gene network (Fig. 6c)
indicates that the first metagroups (MG1, MG2 and
MG3, with higher silhouette width > 0.30), include more
specific mesenchymal-stromal functions (e.g. mesoderm
formation, collagen organization, cell-to-cell adhesion),
and appear more detached to the rest of functional
metagroups. By contrast, MG7 and MG8 (showing sil-
houette width < 0.25) are more promiscuous, with
greater overlap and many edges cross-linking multiple
genes. The functional annotations for these metagroups
are more diffuse or general (e.g. cancer, protein tyrosine
phosphatase activity).
Regarding the genes, some are included in many func-
tional metagroups, as ITGA5 (integrin alpha-5, CD49e
fibronectin receptor), revealing a more central role. In
fact, this gene is connecting five metagroups in the net-
work: MG3, 5, 7, 8 and 9. CD49e fibronectin receptor is
known as essential for the cell attachment to the
extracellular matrix (ECM); but, intracellularly, it is
involved in the formation of adhesion complexes with
cytoskeleton proteins and in the activation of kinases
that regulate signaling of growth, division, survival,
differentiation, migration or apoptosis. The multiple
regulatory functions that this protein integrates en-
dorsed the network position that it presents. Likewise,
another gene central element is the mitogen-activated
protein kinase kinase (MAP2K1), which is found as
acting as connection point for several metagroups:
MG3, 4, 5 and 8. This enzyme lies upstream of the
MAP kinases pathway and is essential for signal trans-
duction. Other genes connecting more than two
metagroups in the network are: ACTN1, GJA1, ILK,
MYOF, PDGFRB, PDLIM7, RAB2A, SORT1, VCL.
To add another layer of information, we also investi-
gated whether genes connecting separate functions
within this mesenchymal lineage network (i.e. genes that
are more central in the network) might present higher
or lower evolutionary conservation. To achieve this, we
incorporated sequence conservation information, based
on the exonic coding regions, to each gene of the func-
tional network. Additional file 12 contains the calculated
conservation scores of the complete list of genes. In the
network, the conservation is displayed as the node
colour, scaled from orange to blue, from least to most
conserved genes, respectively. As a whole, we observed
that the less conserved genes (i.e. genes more recent in
(See figure on previous page.)
Fig. 6 Mesenchymal lineage signature. a Venn Diagrams showing the cross-flow of differentially expressed genes from the three approaches
presented that contrast MSCs to HSPCs. Colour code for tissue-MSCs: BM (red), PL (blue), AD (green). b Summary table of enrichment in biological terms
(MG =Metagroup): Metagroup refers to a functional cluster that gathers functionally associated genes from the mesenchymal lineage signature. The
same MG colour code is applied in the network. The value Silhouette width measures the closeness between biological terms within each metagroup.
The higher the Silhouette width, the more closely related are the metagroup terms. P-values give the enrichment significance to each
metagroup. c Functional network. Ball-nodes represent genes. Links represent functional association between genes based on shared bio-
logical annotations. Squared nodes represent the metagroups of genes sharing functional annotations. Conservation information per gene
(based on exonic sequences) has been implemented under a yellow-blue scale, from less to highly conserved scores, respectively
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evolution) belong only to one functional metagroup (e.g.
CDC42EP3, CDKN2B, SDC4, STS), but the most con-
served are usually connected to several functional
metagroups (e.g. CASK, ILK, GJA1). This is a trend con-
sistent with the idea that conserved genes may be more
multi-functional, since they are more ancient and can
acquire new roles along evolution. For example, we
identified CASK as a highly conserved gene that links
MG5 and MG9. This gene encodes a membrane-associ-
ated calcium/calmodulin-dependent guanylate kinase (a
serine kinase). The known functions of CASK indicate
that it is a scaffold transduction protein located at
synapses in the brain that contributes to neural devel-
opment, maintains the morphology of neuron dendritic
spines, and regulates cellular interactions at the pre-
synaptic site. It is clear that this protein detected in
MSCs will have other functions in the stromal niche,
showing that it is a multi-functional gene. Among the
less conserved genes we found, for example, CDKN2B,
CDC42EP3, CCL2, LAMP1, STS and THY1 (CD90).
The presence of the MSCs marker CD90 in this list might
indicate that more recently evolved genes may also be
more specific within the mesenchymal signature.
MSCs gene coexpression network
The network presented in Fig. 6c corresponds to a func-
tional gene network derived from the enrichment ana-
lysis perforrmed with the 489 gene signature obtained
for the MSCs. To complement this network analysis, we
also built a coexpression network derived from the tran-
scriptomic data, i.e. from the expression values of the
489 genes along the exon arrays in 15 samples of the dif-
ferent cell types studied (that is, an experimentally-
driven network). We calculated the coexpression using
the Pearson correlation, and we applied a stringent cut-
off to select the pairs with correlation coefficient r ≥ 0.95
to identify the most correlated gene pairs. We provide
an Additional file 13 presenting this network. In this
analysis, we highlight the genes that correspond to
known CD markers (16 CDs) and to transcription fac-
tors (11 TFs) to better illustrate possible interesting
links. Some genes like the receptors FGFR1 and
PDGFRB are highly connected in both networks (Fig. 6c
and Additional file 13), indicating that they are relevant
to the nature of the MSCs. To allow a more detailed ex-
ploration of the coexpression network built, we provide
a Cytoscape file that includes all the interactions derived
from the correlations and it incorporates 447 genes and
9969 interactions (Additional file 14).
Functional analysis of the genes expressed in specific
subtypes of MSCs
Figure 6a presents the genes detected as commonly
overexpressed (up-regulated) in the contrast of all the
MSCs versus the HSPCs, which provided an intersection
set of 1303 genes. As a contrast to this common set, we
also investigated the genes and gene functions that were
specific to each subtype of MSC. To do this, we selected
the genes found overexpressed in each tissue-MSC when
compared with the other stromal cell types. These com-
parisons provided: 281 genes for AD-MSCs, 421 genes
for BM-MSCs and 531 genes for PL-MSCs; and corre-
spod to the gene lists derived from the union of the data
represented in the Venn diagrams in Fig. 4f. These three
gene lists were submitted to a functional enrichment ana-
lysis to identify their biological meaning using DAVID
functional enrichment tool (Methods). A first view of
these results (included in Additional file 15), shows that
these lists include genes that correspond to a set of com-
mon biological terms: signal peptide, extracellular matrix,
glycoprotein and secreted protein; that correspond to func-
tions that are enriched in all the tissue-MSCs but not in fi-
broblasts, indicating that these cells have a tendency to
produce much signaling and secreted proteins, often
present in the extracellular matrix. Looking for more spe-
cific functional profiles, we observed that AD-MSCs and
BM-MSCs showed a strong enrichment for terms like
skeletal system development or embryonic skeletal system
development, that indicate a closer association with bone
differentiation and skeleton maintenance. We also ob-
served that homeobox genes (HOXA, HOXB, HOXC,
SIX1, SIX2) were highly present within these functional
annotations, together with other genes like: ACVR2A,
ALPL, GAS1, MGP, TGFB2, TGFB3, TGFBR2. Several of
these genes are related to calcium homeostasis and bone
morphogenesis or to growth and differentiation in specific
cellular contexts; highlighting the functional similarity of
the MSCs coming from bone marrow or adipose tissue.
Overlapping with other reported MSCs gene signatures
Once we analysed human MSC expression profiles and
outlined several stromal cell-, tissue- or lineage-associated
gene signatures, we searched public databases and publi-
cations to find which genes were previously reported using
similar approaches. In Tables 4 and 5, several human
MSC transcriptomic studies have been summarised, and
the reported MSC gene signatures ordered and compared
to the outcomes of our study. The overlapping propor-
tions with different datasets are variable, but the similarity
is rather significant, being aware of the technological
chages along time, the differences in expression platforms
as well as the use of different data handling protocols. In
this way, we found several genes included in our MSCs
lineage signature that repeatedly appeared in gene lists
produced in similar published works. Table 4 presents a
featured overview of the overlap of the MSCs lineage sig-
nature proposed with other studies (highlighting in bold
in the last column the genes that appear in more than one
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Table 4 Review of gene signatures previously published for MSCs and comparison with the proposed MSC lineage signature of 489 genes
Reference Organism Cells types in contrast DE features Statistical
significance threshold




Human Four MSC types (BM, AF, AM
and CB) vs 6 whole sampled
tissues (brain, heart, lung, liver,
kidney, and muscle)
47 genes commonly




Human U133A GeneChip (Affymetrix)
22,000 probe sets that span 14,500
genes
21 genes in the MSC lineage signature: ACTN1,
ADAM9, ANXA5, CALU, CAV1, CTGF, KDELR3,
MCFD2, NNMT, NT5E (CD73), LOX, LOXL2,
PHLDA1, PLOD2, S100A11, SERPINE1, SMURF2,
TAGLN, TIMP1, TPM4, UAP1
Kubo et al.
2009
Human BM-MSC vs differentiated cells
(FIB included)
148 genes UP in BM-
MSC
>2-fold change Affymetrix Human Genome U133 plus
2.0. 54,000 probe sets / 38,500 genes.
Differentiated cells include FIB,
osteoblasts, adipocytes and
chondrocytes.
14 genes in the MSC lineage signature:
ADAMTS5, CCND1, FHL2, GDF15, IGFBP3, LOX,




Human AD-MSC or FIB vs their lineage
derived cells
211 genes UP versus
cells differentiate to 3
lineages




16 genes in the MSC lineage signature: CRISPLD2,
HTRA1, IGFBP5, LAMB1, MARCKS, NNMT, PSAT1,
REXO2, RPS27L, S100A11, SARS, SERPINF1,
TMEM165, TMEM47, VAMP3, WARS
Jääger et al.
2012 [41]










38 genes in the MSC lineage signature: ACTN1,
ADAM9, ANXA5, ARF4, C1R, C1S, CALU, CAV1,
CCND1, CD63, CKAP4, CLIC4, CORO1C, CTGF,
CYB5A, DDAH1, DDR2, DSP, ELL2, FRMD6, FTL,
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list). Some of the genes in these genesets are already
known as phenotypical hallmarks of the mesenchymal
identity, like the biomarker CD73 (NT5E). Others are
known actors in epithelial to mesenchymal transitions:
IGFBP3, DDR2, LOX, LOXL2 [18]. Another gene present
in several of the published lists derived from MSC studies
is SMURF2, an E3 ubiquitin ligase that seems to cooperate
with SMAD7 in preventing myofibroblast differentiation
via TGFbeta receptor destabilisation [19]. RHOC is an-
other interesting gene product that encodes a member of
the RHO family of small oncogenic GTPases, and pro-
motes reorganisation of the actin cytoskeleton, thus regu-
lating cell shape, attachment and motility. Finally, PLOD2
is an enzyme that catalyses the lysyl-hydroxylation in col-
lagen peptides, critical for the stability of inter-collagen
crosslinks. All these biological functions are deeply related
to the stromal cells niche supporting the value of the
MSCs lineage signature found.
As a contrast inside the stromal lineage, we also found
genes that appear to be specifically associated to MSCs
but not expressed in FIBs (Table 5). These genes show
interesting roles, for example: the family of HOX regula-
tory factors (HOXA5) involved cell differentiation, cell
adhesion/migration and cellular development; or several
collagen molecules highly expressed in MSCs (COL4A1,
COL5A1). These contrasts also reveal specific up-
regulated genes just in FIBs, like KIT, and genes of the
MMP family (MMP1 and MMP3) that were also found
in the set of 60 genes that we assigned to be fibroblast-
specific (see Table 3 and Fig. 4f ).
Discussion
Mesenchymal stromal/stem cells phenotyping
The term “mesenchymal stromal/stem cell” summa-
rises a complex cellular entity that can be isolated
from diverse tissues in the human body, sharing simi-
lar morphology, growth conditions, cytometric pat-
terns and in vitro differentiation capacity. Despite
these parameters that have been agreed and standar-
dised for MSCs [20], a detailed biomolecular profiling
of this cell type is lacking; and it is common to find
fluctuations in the identification of these cells and in
the reports of gene or protein markers assigned to
them. In fact, many research articles about their spe-
cific phenotypic markers have been published (as
summarised in [21]). Multiple efforts have been
undertaken to discover biomarkers that allow homo-
geneous isolation of these cells. Despite these efforts,
the field is still open to deeper molecular character-
isation. In this work, we have conducted a broad
genomic-based approach that provides a data-driven
characterisation of the genes activated in the MSC
phenotype, reinforcing some already proposed know-
ledge and providing new insights inaccessible to pre-
vious procedures (Tables 4 and 5).
Table 5 Comparison of fibroblastic signatures previously published against our differentially expressed genes in equivalent
contrasts
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set RZPD3 (two colour arrays).
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Multiplex mRNA-sequencing 14 genes UP in FIB vs MSCs: ANPEP,
CDC25B, CLDN11, CTSK, CXCL12, DNM1,
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set RZPD3 (two colour arrays).
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Multiplex mRNA-sequencing 13 genes DOWN in FIB vs MSCs: BGN,
CDH2, GGT5, ID3, COL4A1, COL5A1,
COL11A1, KRT18, LOXL2, NDFIP2,
TAGLN, TNS1, TPM1
Genes appearing in more than one published signature are highlighted in bold
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Previous studies on primary stromal cells and the bone
marrow niche
Several relevant publications [22–25] have contributed
to the characterisation of the cellular and molecular
components of the bone marrow niches (i.e. endosteal
osteoblasts, perivascular stromal cells, endothelial cells,
Cxcl12 abundant reticular cells, Lepr+ stromal cells,
Nestin+ mesenchymal progenitors) where the HSCs res-
ide, proliferate, mobilise or differentiate. The main con-
sideration we need to be aware of is the fact that all this
information comes from experiments in vivo in “mice”.
Therefore, the advances of these reports cannot be dir-
ectly extrapolated to the human bone marrow micro-
environment. However, these studies are of broad
interest to contextualise previously described interac-
tions from mice into the human hematopoietic niche.
We discuss these and other related studies that provide
information about the transcriptomic profiling of MSCs.
The highly expressed chemokine CXCL12 is a potent at-
tractant and retainer of both HSCs and MSCs, critical for
maintaining hematopoietic stem and progenitor cells
(HSPCs) in a quiescent state. CXCL12 abundant reticular
cells (named “CAR cells”) were first shown to guide a de-
pletion of HSCs when the Cxcl12 gene was knocked-down,
as well as severely impair the adipogenic and osteogenic
capacities of these stromal cells [26]. Moreover, dele-
tion of CAR cells reduces the number of B-lymphoid
progenitors [27]. This HSC niche-related cytokine was
shown as expressed in CD146+ perivascular mesenchy-
mal cells in humans [11], with capacity to generate
osteoblastic cells and promote HSC maintenance.
Niche cells for HSC maintenance are marked by
Nestin (Nes), an intermediate filament protein found in
self-renewing mesenchymal stem cells (MSCs) [22].
Nes+ cells express very high levels of Cxcl12. Futher-
more, PDGFRα+/Sca1+ (PαS) cells have been suggested
to comprise bone marrow MSCs [28]. In fact, the fre-
quency of CFU-F, a hallmark of MSCs, in Prx1+ PαS
cells is much greater than that reported for Nes+ cells,
suggesting that Prx1+ cells are indeed mesenchymal
progenitors [24].
Apart from highly expressing CAR cells and MSCs,
other stromal cells committed to osteogenic lineage or
endothelial cells also express Cxcl12, though in lower
levels. Several studies have evaluated the functional im-
pact of Cxcl12 removal in different stromal populations
of the niche [23, 24, 29], thus defining distinct specia-
lised niches for HSC maintenance, HSC retention, and
the generation of certain lymphoid progenitors. Deletion
of Cxcl12+ in osteoprogenitors (Sp7 or Osterix positive
cells) causes a significant reduction of T- and B-cell pro-
duction, and fewer early lymphoid progenitors. Leptin
receptor (Lepr) is present in perivascular sinusoidal stro-
mal cells that express high levels of stem cell factor
(SCF), which was previously reported as essential for
HSC maintenance [23]. Lepr is also involved in a novel
hematopoietic pathway that is required for normal lym-
phopoiesis. Another role has been suggested for Cxcl12,
derived from Lepr-marked cells, that was related to the
retention of HSCs rather than to their maintenance. This
role comes from the observation that reduction of
Cxcl12 expression within the sinusoidal stromal com-
partment does not alter HSC or progenitor numbers,
but induces the mobilisation of HSCs and progenitors to
the spleen and peripheral blood.
Through analysis of the data generated by our work
that showed overexpressed genes in different human
tissue-MSCs compared to HSPCs, we can derive several
interesting observations related to the markers identified
in mice studies: (i) we show the presence of CXCL12,
LEPR, KITLG in the specific expression of BM-MSCs;
(ii) CXCL12, but not LEPR, was also overexpressed in
AD-MSCs; (iii) PL-MSCs did not show overexpression
of CXCL12 or LEPR; (iv) PDGFA, PDGFC, PDGFRB and
PDGFRA are generally expressed in MSCs from all the
tissues studied; (v) RNA-Seq data showed a strikingly
higher expression level of the Nestin gene (NES) in hu-
man PL-MSCs compared to BM-MSCs [16].
Consistent finding of CDs to mark the MSCs
The study of MSCs in primary cultures implies the
growth in heterogeneous populations with unknown
proportions of differently committed cells. Thus,
expressed genes may strongly vary from culture to cul-
ture, setting the reason why signature or biomarker
characterisation is sometimes irreproducible. In other
words, it produces an increased rate of false positives in
differential expression and a reduced true positive rate.
The present work addressed these problems applying
several strategies to solve them: (i) integration of mul-
tiple datasets including a large number of samples of our
interest collected from different studies; (ii) construction
of an adequate cell biology framework with a well-
distilled and contrast-minded sample cell types selection;
(iii) application of robust re-sampling techniques to find
stable and reproducible signals. In this way, DE genes
yielded by the multiple analyses produced steady and re-
liable expression signatures. The genes selected may not
be the most strongly expressed for a sample category in
a single test. Instead, they presented a rather constant
differential expression pattern along the samples, signifi-
cantly surpassing the iteraction tests. Thus, despite pos-
sible variability in the samples, genes presenting subtle
changes stable along samples, were preferably captured.
Proof of the methodology success is given by the re-
trieval of official MSC CD marker genes (i.e. CD73,
CD90, CD105) in the BM-MSC signature (Table 1).
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CD146 (melanoma cell adhesion molecule MCAM, a
determinant of hematopoietic perivascular niches) stands
steadily over-expressed in BM-MSC cultured populations
when they are repeatedly compared to hematopoietic pro-
genitors and dermal fibroblasts. Analogous expression
profiles had been observed by other molecular techniques
and independent signatures [9]. Covas et al. [9] reported a
close transcriptomic relationship between CD146+ peri-
vascular cells from BM-MSCs; also segregating them from
fibroblasts, which did not expressed it. Moreover, it has
been observed that therapeutically applied BM-MSCs pre-
serve a population of CD146+ perivascular cells. Another
7 CDs out of the 28 listed in the BM-MSC signature have
been used as molecular markers for MSC and other stem
cells (CD13, CD49e, CD58, CD73, CD90, CD105 and
CD140b) (updated from Calloni et al.) [21]. Considering
the correlation with previous knowledge, novel interest
may be focused on the other highly confident CDs pre-
sented in this work. These molecules may compose the
distinctive body of CDs available for BM-MSCs (Table 1).
The fibroblast in the stromal cell context
Pedemonte et al. published an extensive transcriptomic
study using mouse MSCs and related cell types [30]. A
collection of 486 microarrays from many tissues and cell
types allowed the allocation of the mesenchymal lineage
in a comprehensive panel of lineages. Interestingly, the
closest cell type that clustered with BM-MSCs was the
fibroblastic type (specifically MEFs, the murine embrion-
ary fibroblasts). A transcriptomic-based study was also
reported by Chang et al., that provided an unsupervised
comparative analysis and clustering of human fibroblas-
tic populations obtained from different sites of the hu-
man body [8].
The stromal cells studied here presented clear dif-
ferences between them, attributed mainly to their
tissue-linked origins. Differences observed between
the fibroblasts and the MSCs categories are not
large, although the fibroblasts are considered the
stromal type with the highest expected degree of dif-
ferentiation. This means that the MSC populations
that we are investigating, in terms of their trancriptome,
are a much closer cell type to the fibroblast than initially
expected. Our flow cytometry data also supported the
similar expression of CDs between MSCs and fibroblasts.
This similarity has been previously reported [31, 32] and
Haniffa et al. even proposed that fibroblast and MSCs are
functionally equivalent [32]. Controversial results about
the differentiation potential of fibroblasts toward adipo-
blasts, chondroblasts or osteoblasts, keep the fibroblast
cell under questioning [33–35]. The work from Alt et al.
[35] encountered human skin fibroblast cultures capable
of differentiating and forming CFUs in vitro. As the separ-
ation between MSCs and fibroblasts seems small, we
found more fruitful the contrasts of MCSs isolated from
different tissue origins against HSPCs to extract a mesen-
chymal multilineage defining gene catalogue.
Mesenchymal lineage signature
We collected the gene sets found to be up-regulated in
MSCs relative to hematopoietic stem cells from all of
the performed contrasts: (i) the three contrasts from the
tissue-specific MSCs versus HSPCs (presented in Fig. 6a),
and (ii) the 150 re-sampled contrasts obtained through
the meta-analysis approach of BM-MSCs versus HSPCs
(Additional file 6, contrast 1). These gene sets were ana-
lysed, to find the overlapping, and also compared with
the genes found “ON” in the MSCs footprint (obtained
with RNA-Seq) [16]. Following this integrative approach,
we were able to delimit an expression core of 489 com-
mon genes that support and maintain the multipotency
of the mesenchymal lineage. The functional enrichment
of this MSC gene signature indicates a strong osteogenic
association of the genes, that has been postulated as the
most frequently chosen path of the cellular commitment
programs for MSCs. Moreover, it has been observed that
the osteogenic potential capacity is lost the last when a
progressive in vitro model of multipotency is established
[34, 36].
Charbord and colaborators [25] defined a large gene
signature (including 481 mRNAs) whose expression is
associated to the support of the hematopoietic niche.
This signature inluded most of the aforementioned
genes related to the bone marrow niche. We compared
the Charbord signature with the up-regulated genes de-
tected in each of our tissue-MSCs (derived from the
comparisons versus HSPCs). The number of genes
matching each overexpressed gene-list was: 121 genes
in AD-MSCs, 125 in BM-MSCs, and 119 in PL-MSCs.
This result indicates that the BM-MSCs are the closest
to the described hematopoietic niche, and are closely
followed by AD-MSCs and PL-MSCs. However, a re-
cent publication by Reinisch and colaborators [37]
stated that only BM-MSCs, and not other tissue-MSCs,
were capable of developing an endochondral ossifica-
tion of human cells in a mice model that was preceded
by the formation of a functional hematopoietic niche.
Our data may be compatible with this notion if we con-
sider that just 4–6 genes can make a significant differ-
ence, although proper experimental testing with these
genes will be the only way to prove the specificity of
the BM-MSCs versus other subtypes.
Some genes derived from the network reconstruction
Aided by the graphical view of a network, genes that be-
have like hub connectors of functions could be uncovered,
opening the door to new potential regulators of the mes-
enchymal system. For example, SORT1 gene (sortilin 1)
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occupies a hub position between three functional
metagroups that connect vesicle trafficking, tyrosine
phosphorylation signalling and molecular processes
usually altered in cancer (Fig. 6c). The protein encoded
works as a sorting receptor in the Golgi apparatus
required for protein transport to the lysosomes. Inter-
estingly, it has been shown that SORT1 promotes min-
eralisation of the extracellular matrix during osteogenic
differentiation by scavenging the extracellular lipopro-
tein lipase produced by adipocytes [38]. This gene
might be an actor of the fine equilibrium between dif-
ferentiation paths.
Transcription factors
Transcription factors (TFs) are the principal regulators of
fate decision. In the MSC lineage signature we found 13
TFs: ARID5B, CREB3, EPAS1, FHL2, GTF2E2, GTF2IRD1,
ID3, LMO7, SNAI2, TAF13, TEAD3, TULP3, ZNF532
(Tables 4 and 5). Two of these TFs have enrichment in
transcription factor binding sites (TFBS) in the pro-
moters of a significant number of targeted genes
within the 489 MSC signature: CREB3 (301 targets)
and TEAD3 (210 targets). TF SNAI2 has been largely
documented as a central booster of mesenchymal
phenotype, as occurs along EMT processes (epithe-
lium-mesenchymal transitions) [39]. SNAI2 transcrip-
tionally represses expression of E-cadherin, but may
act as an activator depending on the biological con-
text. Recently, it has been intricately related to osteo-
blast maturation through interaction over RUNX2 and
CXCL12 promoters [40]. Another nine factors are ac-
companying SNAI2 into this signature, including ID3
(inhibitor of DNA binding). ID3 is a helix-loop-helix
(HLH) protein that can form heterodimers with other
HLH proteins, thus preventing them to bind their
target DNA regulatory regions. It is known that ID3
inhibits the skeletal muscle and cardiac myocyte differ-
entiation by seclusion of E2A-complexes from E-box
enhancer of muscle creatine kinase. In our data, ID3,
together with PAWR (or PAR4), was robustly overex-
pressed in BM-MSCs relative to fibroblasts. PAWR is a
pro-apoptotic WT1-interacting protein that functions
as a transcriptional repressor. PAWR induces apop-
tosis by activation of the FAS pathway, and co-
parallelly by inhibition of NFKB in certain cancer cells,
specifically prostate cancer. Intriguingly, SNAI2, ID3
and PAWR have been generally discovered by their
function as transcriptional repressors.
Tissue-specific MSC genes
Differences between stromal populations derived from
various tissues are becoming more evident, and repre-
sent a source of heterogeneity within the mesenchymal
phenotype. All stromal cells are essentially able to
differentiate into the three mesenchymal fates in vitro,
although they do not follow the same molecular paths.
The cells seem to keep expression “memory” of source-
specific genes that travel along during the differentiation
process [41]. Recent transcriptomic studies developed in
murine endothelial cells from a plethora of tissues have
also manifested the tissue-specificity of their molecular
signatures, heterogeneity that is explained by their func-
tion in maintenance and regeneration of the different
microenvironments [42].
Using our in-house dataset to contrast tissue popula-
tions against each other, we were able to describe a rep-
ertoire of tissue-specific genes from four tissue stromal
populations: bone marrow, placental and adipose tissue
MSCs also in addition to dermal fibroblasts. Curiously,
AD-MSC showed the lower numbers of differentially
expressed genes in the comparisons with the other
MSCs, showing the smallest number of exclusively adipose
tissue genes when compared to the rest of the stromal cells
(Venn Diagrams in Fig. 4f). These result resemble those
found by Jaager and co-workers [41] (Tables 4 and 5), who
suggested that the switch of stromal lineage to adipocyte-
specific cell type require fewer genes than the switch to
osteoblast- and chondrocyte-specific cell types. This appar-
ently less specific MSC could sustain a less functionally
specialised MSC in the adipose environment or possibly a
more dormant cellular state.
Going further in the tissue-specificity analysis, CD
and cytokine patterns of stromal cells were also stud-
ied. CD106 (vascular cell adhesion molecule VCAM1)
appeared overexpressed exclusively in BM-MSCs. It
has been long known that this marker is associated to
bone marrow stromal cells. Moreover, a population of
human cells with overexpression of two genes,
VCAM1+/STRO1++, have been shown to develop
bone tissue in vivo following ectopic transplantation
to mice [43]. VCAM1 becomes down-regulated by
cleavage during G-CSF mobilisation of HSPCs, confer-
ring it an implied function in maintenance of the
hematopoietic niches [44]. Other transcriptomic reports
have also listed CD106 as expressed in BM-MSCs [31]. All
these data pinpoint this gene as a BM-MSC specific gene.
Beyond the bone marrow, other CD markers have been
discovered for placental MSCs; like for example CD56
(NCAM1) that has been previously linked to highly clono-
genic MSCs (i.e. small stromal cells that divide more rap-
idly and are detected frequently in preparations from
younger donors) [45].
Another singular result from the tissue specificity ana-
lysis is the higher expression of TWIST1 and TWIST2
in dermal fibroblasts. The same outcome was previously
associated to steady osteo-progenitor states of MSCs
[43, 46]. TWIST1 and TWIST2 have been implicated in
cell lineage determination and differentiation, therefore
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they may be up-regulated in more differentiated and
committed stromal cells, as the fibroblasts are [46].
Their strong presence in skin fibroblasts compared to
other stromal types involves a role in fate determination
and more probably in the restriction of other differenti-
ation paths. In fact, low expression of these genes has been
correlated with low osteogenic differentiation potential.
Cytokines clustering around each tissue also defines
the microenvironmental cues of specific signalisation.
We found LEPR gene is specifically expressed in our
human BM-MSCs. LEPR is the receptor for leptin, an
adipocyte hormone that regulates body weight through
fat metabolism, and has a role in hematopoietic path-
ways. In mice, sinusoid-associated leptin receptor
(LEPR)+ cells maintain HSPC perivascular residence in
the bone marrow [23]. In this way, LEPR+ stromal cells
are key regulators of marrow homeostasis and the main
bone producers in the adult mouse [47]. As far as we
know, the expression of LEPR in humans had not been
explicitly reported before.
CCR2 (CD192) activation by CCL2, as other receptor
and cytokine partners found between HSPCs and BM-
MSCs, mobilise monocytes during inflammatory
responses and also seem to promote mobilisation of
mesenchymal cells out of the marrow [48]. Activin re-
ceptors ACVR1 and ACVR2 also appear to be
expressed in MSCs in the bone marrow. Type I and II
receptors form a stable complex after ligand binding
and transduce signals of BMPs and other TGFbeta
family members. A mutation in ACVR1 (ALK2) is
causative of fibrodysplasia ossificans progressiva, a dis-
ease that progresses with heterotopic ossifications in
muscles, tendons, ligaments and general connective
tissues. The mutation confers constitutive activity to
the BMP type I receptor and sensitises mesenchymal
cells to BMP-induced osteoblast differentiation and
bone formation [49]. As a new finding, the production
of the inhibin ligand by HSPCs (INHBC) may be con-
trolling the balance of differentiation of MSCs toward
osteoblasts. Functional experiments are needed to un-
ravel the interplay effects of this pathway.
Conclusions
Many molecular studies have shed light into the origin,
identity and function of stromal cell populations within
the bone marrow, although most of the knowledge has
been only assayed on mouse models. The bulk of human
MSCs currently in use for clinical therapies present a
phenotype only partly described to date. Through the
data provided in this work and the analytic methods de-
veloped, we were able to obtain a detailed profile of the
transcriptional phenotype of human mesenchymal stem/
stromal cells. Relationships based on transcriptomic dis-
tances were explored among different tissue-stromal
cells and with other non-mesenchymal related cell types.
To extract the common traits of the inherently hetero-
genic population of cultured MSCs from the bone mar-
row we applied a re-sampling protocol over a large
integrated compendium of genome-wide expression data
samples. We also extended the view to the interconnect-
ing wires with hematopoietic housemates, performing a
detailed comparison of the genome-wide expression pro-
files of MSCs and HSPCs. Up-regulated genes in the
mesenchymal lineage against the hematopoietic lineage
yielded a signature of 489 genes. Functional relationships
were decrypted and potential regulatory genes of lineage
commitment were postulated. Genes proposed for
markers of stromal phenotype have been revised, includ-
ing those that are CD markers, cytokines or regulatory
elements like transcription factors. Tissue-specific gene
expression sets associated to some stromal cell subtypes
(i.e. AD-, BM- or PL-MSCs) were also uncovered. Finally,
all the gene signatures and profiles depicted in this work
are provided open to new investigations that may expand
the understanding of the mesenchymal cell biology.
Methods
Isolation of human primary cells
All of the procedures performed in the current study
with human samples are in accordance with the
Declaration of Helsinki and collected after signed in-
formed consent was obtained (as formally approved by
the Ethics Committee of the Health District and the
University Hospital of Salamanca).
Human AD-, BM- and PL- MSCs from healthy in-
dependent donors were isolated and expanded in
vitro. Placental samples correspond to healthy new-
borns (n = 8), taken postpartum, immediately after
delivering. Chorionic sections of 80 to 100 g were
collected in aseptic conditions [50]. Each sample was
washed thoroughly in normal saline solution, dis-
sected into pea-sized fragments and enzymatically
digested in 250 ml DMEM-LG medium (Gibco, Invi-
trogen), with 100 U/ml Collagenase type I (Gibco,
Invitrogen) and 5 μg/ml DNase I (sterile, Roche). The
mixture was incubated in a shaker for 2 h, at 37 °C
[51, 52]. Cell suspensions were filtered through
70 μm strainers (Becton Dickinson), centrifuged
(300xg, 10 min, 20 °C), resuspended in Hanks Solution
(Gibco, Invitrogen) and processed for mononuclear frac-
tion separation (MNCs). The bone marrow and adipose
tissue samples correspond to healthy adult donors. Bone
marrow samples of 10 to 20 ml from iliac crest aspirates
(n = 5) were taken under local anaesthesia under insti-
tutional standards [53]. MNCs were separated by dens-
ity gradient centrifugation using Ficoll-Paque® (GE
Healthcare Bio-Sciences), then seeded on a plastic sur-
face (106 MNCs/cm2) with DMEM-LG supplemented
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with 10% FCS (BioWhittaker, Lonza) and 1% penicillin/
streptomycin (Gibco, Invitrogen) [54]. Samples of adi-
pose tissue lipoaspirates (n = 3) were harvested as de-
scribed in [55]. Briefly, collected tissue was centrifuged
(600 × g, 10 min, 20 °C), the cellular supernatant was
separated and enzimatically digested (with 0.2%
collagenase-I at 37 °C for 30 min). Tissue debris was fil-
tered out with 70 μm strainers. Erythrocytes were lysed
with ACK 1X lysing Buffer (A10492 Gibco, Invitrogen).
The resulting cell suspensions were centrifuged (600 X
g, 10 min, 20 °C), washed in PBS and plated under the
same conditions as bone marrow MNCs.
Primary cultures of human skin fibroblasts (n = 5) from
healthy adult donors were provided by the Tissue Engin-
eering Unit, Community Centre for Blood and Tissues of
Asturias [56], and INNOPROT (Ref: P10858: Human Der-
mal Fibroblasts, adult). Cells were grown in vitro for 2–3
passages under the same conditions as MSCs.
Leukapheresis samples (n = 3) from healthy adult do-
nors were harnessed to isolate the fraction of mobilised
hematopoietic progenitor cells (as in [57]). Immunomag-
netic positive selection of CD34 cells was performed
using the CD34 MicroBead Kit (MACS, Miltenyi Biotec)
[58]. Isolated cell suspensions were then submitted to
transcriptional analysis.
Cells were allowed to adhere for 3–5 days in a 37 °C,
5% CO2 atmosphere. The medium was completely chan-
ged twice a week thereafter. When confluence was
reached, adherent cells were trypsinized (Trypsin-EDTA,
Gibco, Invitrogen) and replated for culture expansion
(seeding at 3,000-5,000 cells per cm2) [59]. Cell counts
were performed within each passage.
Growth rates were evaluated calculating the population
doubling times from the first to the sixth passage, follow-
ing the formula: PDT = TExpan * (log(2) / log(Q2 /Q1)).
The Wilcoxon test searched for significant differences be-
tween cells.
Flow Cytometric controls
All stromal cells included in this study were tested by flow
cytometry under the terms of the ISCT minimal criteria
[20]. MSCs (~106 cells) were harvested, resuspended in
PBS, and incubated with conjugated antibodies using the
following panel: CD90-FITC, CD14-PE, CD45-PerCP/
CD34-FITP, CD73-PE, HLA-DR-PerCP/CD44-FITC, 166-
PE, CD19-PerCP, CD105-APC/CD11b-FITC, CD33PE,
7AAD-PerCP (FITC: fluorescein isothiocyanate, PE:
phycoerythrin, PerCP: peridinin chlorophyll protein, APC:
allophycocyanin; Becton Dickinson Biosciences). 100,000
cell events per culture were acquired in a FACSCalibur
flow cytometer (BD Biosciences) connected to the Cell-
Quest program (BD Biosciences). Fluorescence-based ex-
pression of CD markers per event was analysed using the
Infinicyt software (Cytognos).
In vitro differentiation assays of MSCs
MSCs were plated and grown with each specific differenti-
ation media (Miltenyi Biotec). For osteogenic and adipo-
genic induction, MSCs were adhered to 9.6 cm2 slide
flasks (Nunc, Roskilde). Osteoblastic alkaline phosphatase
activity was evaluated by NBT/BCIP colorimetric reac-
tions (nitroblue tetrazolium chloride/5-bromo-4-chloro-3-
indolyl-phophate) (Roche). Adipogenesis was observed by
Oil-Red-O staining of lipid vacuoles (Certistain Merck
KGaA). Pelleted cells placed in conical tubes were also
conditioned towards chondrogenic differentiation. The
resulting cells were embedded in paraffin, cut into 5 mm
sections and Hematoxylin-Eosin-stained for evaluation of
cartilage matrix formation [60].
General calculations and statistics
All data analyses and graphics have been produced using
the R statistic environment. General functions such as
boxplot, image, qplot (from ggplot2 library) or wilcox.test
were applied over the different data presented here. Spe-
cific methodologies are explicitly cited along different
sections of this manuscript.
Microarray data repository for a meta-analysis approach
A collection of 264 arrays were recruited from the GEO
database [61]. Details and references of each dataset in-
cluded are be found in Additional file 4. Data were
mined considering the following inclusion criteria: (i)
Technical issues: raw CEL files available, MIAME cri-
teria surpassed, Affymetrix platform HG-U133 A and B
(when both were available for each sample) or HG-U133
Plus 2.0. (ii) Biological issues: cell type (MSCs, HPCs/
HSCs, other stromal cells), primary cell populations,
outgo cytometric standards, non-pathological state, non-
drug treated. (iii) Annotation issues (for research inter-
est): tissue origin, culture passage, differentiation state,
and differentiation method. Following these criteria, the
whole compendium of samples collected for the study
was 264, but this set was only used in the global cluster-
ing analysis, because for the differential expression com-
parisons we subselect only primary stem cells isolated
from bone marrow (i.e. BM-MSCs and HSPCs from
bone marrow), that are the ones included in the subset
of 119 samples. In the set of 264 samples, as indicated in
Additional file 4, there are quite a lot of MSC samples
that correspond to stimulated cells (e.g. 24 samples from
dataset GSE10315 were stimulated with BMP2 or with
TGFB3) or differentiated cells (e.g. nine samples from
dataset GSE9451 were MSCs differentiated to adipo-
cytes, chondrocytes or osteoblasts). Moreover, in the
compendium of 264 samples, some HSPCs were not iso-
lated from bone marrow but from umbilical cord blood
(e.g. eight samples from dataset GSE10438 and 9
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samples from dataset GSE3823) or from whole periph-
eral blood (e.g. six samples from dataset GSE3823).
Microarrays pre-processing and normalization
Different array platforms were all integrated in one. To
place the whole dataset into the same analysis workflow,
paired microarrays from HGU133A and HGU133B were
unified into a new HGU133 Plus 2.0-based array. Union
of the probes from both platforms were considered, and
the highest intensity signal was taken into account when
measures from the two platforms were available. Probe
position coordinates were allocated following the Plus
2.0 scheme. An ad-hoc R chip definition file (CDFs) with
complete unambiguous mapping of the probes from
HGU133 microarrays to human genes (Emsembl) was
used: GeneMapper R package published in [62]. In this
way, the expression signal per gene was calculated. A
compendium of 16,979 features uniquely identified as
Human Ensembl Genes (ENSG IDs, Ensembl database
57) were computed per array. File reading and mapping
was supported by the ReadAffy function from affy li-
brary in R-BioConductor.
Batch effect normalization was addressed by the fro-
zenRMA method [63]. Batch-specific effects per probe
were pre-computed using balanced subsets of the differ-
ent batches recruited and then “frozen” into vectors.
RMA normalization combining information contained
in the frozen vectors was subsequently applied over the
whole repository of arrays.
A sample-to-sample Pearson correlation heatmap of
264 arrays was produced using the average method of
clustering (function hclust). Principal component ana-
lyses were conducted through distinct approaches: using
genes or samples as variables. The prcomp function ex-
tracted the principal components that were graphically
represented using the biplot and scatterplot3d tools, for
two or three components, respectively. The biplot func-
tion generates a vector for each array in the recreated
two-component-space.
Resampling proceedings and differential expression (DE)
For DE analysis a resampling protocol was implemented
in R, together with the limma package protocol to
model and test the statistical contrasts. The set of 119
microarrays corresponding to 50 samples of BM-MSCs,
10 HSPCs, 11 FIBs, 13 OSTBs, 12 dOSTs and 23 stOSTs
(Additional file 4) was used for differential expression
analyses in 6 binary comparisons. These comparisons
are detailed in Additional file 6, that shows four main
contrasts designed. Contrasts 1, 2 and 3, compared BM-
MSCs against other well-defined cell types: (1) BM-
MSCs versus bone marrow HSPCs; (2) BM-MSCs versus
skin fibroblasts (FIBs); and (3) BM-MSCs versus osteo-
blasts (OSTBs). A last group of contrasts (4A, 4B, 4C)
compared several states derived from MSCs toward the
osteoblastic lineage. These last comparisons were merely
used for assaying the behavior of the resampling algo-
rithm, as the data from these transformed MSCs were
quite variable indicating that the experimental proce-
dures applied produced strong and unpredictable effects
in the cells. In the comparisons we labelled the groups
as “Cell Type I” or “Cell Type II” (as indicated in col-
umns B and C of the table in Additional file 6). The re-
sampling approach took subsets of 7 by 7 samples with
replacement (up to 200 times, i.e. 200 iterations), to pro-
duce a collection of DE results for each comparison. To
be precise, each contrast designed with limma was re-
sampled until the contrast results reached a plateau in
which the genes being differentially expressed became
constant. DE was considered statistically significant
when the adjusted p-value was < 0.05 (adjusting for
multiple-testing with FDR method). The stability behav-
iour of differentially expressed genes turned to be spe-
cific to each contrast. Thus, a different limit to the
number of iterations was applied to each contrast (sta-
bility curves reached when the whole re-sampling
workflow was run 100 times may be seen in Additional
file 7). Once a threshold of iterations per contrast was
fixed, genes presenting differential expression along all
the re-sampling iterations were extracted and ranked.
Then, the median of ranks was computed along all the
iterations per DE gene. Each gene rank was assigned
based on FDR adjusted p-values. DE genes were sub-
mitted to functional enrichment analysis through the
DAVID web tool [64].
In-house expression data set of tissue-MSCs, fibroblasts
and HSPCs
Samples from AD-, BM- and PL- MSCs, skin fibroblasts
and HSPCs were analysed using Affymetrix Human Exon
1.0 arrays. Cell samples were processed under the same
controlled conditions. 15 microarrays were hybridised,
including three biological replicates of each cell type.
The platform reached higher coverage than the meta-
analysis approach, attaining the measure of 20,238
unique human gene loci. The full expression signal of
the arrays was normalised and calculated with RMA al-
gorithm (affy package, R-Bioconductor [65]). The dataset
is fully accessible from the GEO database under the
identifier GSE72332.
Differential expression was tested using the limma pack-
age for the meta-analysis approach. Principal component
analysis and heatmaps were done applying the same
methods as in the meta-analysis approach. Likewise, the
biomarker clustering heatmap was generated with the 358
CD marker genes retrieved from Uniprot and recognized
as Ensembl genes.
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Cytokinome pattern analysis
The human pathway Cytokine-cytokine receptor interaction
(hsa:04060) from KEGG database, containing 265 cytokine
genes among the microarray genes, was used for the cytoki-
nome mappings. The KEGG mapping tool was utilized. For
the clustering analysis of cytokine profiles, we applied a fil-
tering step of 50% to the less variable cytokines along stro-
mal cell samples, and then a heatmap image of Euclidean
distances (average clustering method) was produced.
Mesenchymal signature, cross-validations, and functional
enrichment analysis
Intersections of output gene lists from each comparative
analysis were performed using the Ensembl gene symbols.
To give strength to these output gene lists, our previously
published RNA sequencing footprint of MSCs [16] was
crossed with all the signatures produced in this study. Bio-
logical annotation and clustering of enrichment analysis
were performed with the Gene Term Linker tool [66]. A
network presenting the relationships between genes based
on their shared enriched functions was generated using
the FGNet package in R-Bioconductor [67]. Conservation
scores from alignments of 100 vertebrate species (known
as UCSC hg19 phastCons) were annotated with the phast-
Cons100way.UCSC.hg19 package, and then added to the
functional network in yellow-blue colour scale.
Additional files
Additional file 1: Recordings of established stromal cultures (AD-, PL-, BM-
MSCs, and FIBs). Cell counts through passages (“Q1” and “Q2”), expansion
times (“Texpan”) and doubling times (“DoubT”). (XLSX 52 kb)
Additional file 2: Flow cytometry histograms showing standard
immunophenotyping of stromal cell populations studied. (PPTX 204 kb)
Additional file 3: Microscope images of the MSCs differentiation assays.
In vitro multipotency detection by tri-lineage differentiation assays performed
with samples of BM- PL- and AD- MSCs. Left-side photos show MSCs
upon differentiation induction (positive assays). Negative controls (no
induction medium applied) are shown in the photos on the right. (A)
Osteogenic differentiation detected by alkaline phosphatase (AP) activity.
Arrows indicate pools of high AP activity inside the cells. (B) Adipogenic
differentiation detected by fat staining with Oil-Red-O. Arrows indicate fat
vacuoles stained in red inside the cell cytoplasms. (C) Chondrogenic
differentiation detected by tissue three-dimensional growth. Images
show the section of cartilage spheroids stained with Hematoxilin-Eosin.
Arrows denote areas of matrix composition produced by cells embedded in it.
(PPTX 71553 kb)
Additional file 4: GEO dataset references of microarray data repository
and number of samples selected in each of the two meta-analysis steps:
(i) the hierarchical clustering analysis with 264 microarray samples
(SET 264); and (ii) the differential expression resampling protocol with 119
microarray samples (SET 119). (XLSX 57 kb)
Additional file 5: Unsupervised hierarchical clustering of whole-genome
expression profiles. The heatmap gives a comparative view of relationships
among MSCs from three different tissues (bone marrow BM, placenta PL
and adipose tissue AD), hematopoietic progenitor cells (HPC) and
differentiated fibroblasts (FIB). All genes were used for the distance
calculations. The dendrogram of the sample clustering is also shown.
The colour scale provides a view of the distance range. (PPTX 164 kb)
Additional file 6: Output summary of the meta-analysis differential ex-
pression. Notations: BM-MSC = Bone Marrow MSC; HPC = Hematopoietic
progenitor cells; FIB = fibroblasts; OSTB = Osteoblasts; dOST =MSC in-vitro
derived osteoblasts; stOST = stimulated osteoblasts. The ”n” refers to the
number of microarrays. (XLSX 39 kb)
Additional file 7: Performance curves of the re-sampling process that
show the stability of the meta-analysis differential expression. Individual
curves represent each contrast in the study, showing the number of
differentially expressed genes accumulated (y-axis) across the iterations
of the re-sampling protocol (x-axis). Each contrast with re-sampling has
been run 100 times; the mean is shown with a red line. (PPTX 870 kb)
Additional file 8: KEGGmap “hsa04060: Cytokine-cytokine receptor
interaction”. Red-colour boxes are differentially over-expressed genes in
HPCs with respect to MSCs. Yellow coloured genes are over-expressed in
MSCs relative to HPCs. (PNG 63 kb)
Additional file 9: List of 489 protein coding genes included in the
mesenchymal lineage signature produced in this work. The table
provides the gene symbols, ENSEMBL identifiers (IDs), corresponding
UniProt IDs, protein names and description, as well as UniProt protein
families and keywords. The proteins that are known CD markers (CDs) or
transcription factors (TFs) are also indicated. (XLSX 129 kb)
Additional file 10: Table specifying the metagroups (“MG”) obtained
from the functional enrichment analysis and subsequent annotation
clustering of the mesenchymal lineage signature. The parameters used
are detailed along the Materials and Results sections of the manuscript.
Representative genes or terms of each metragroup are denoted in bold
letters. (XLSX 38 kb)
Additional file 11: PCA of the 15 Exon-Arrays dataset using the 489
gene signature build for MSCs. (A) Biplot of the PCA outcome taking 489
genes as observations and 15 exon arrays as variables. (B) 3D plot illustrating
the outcome of PCA taking the genes as variables and showing the 15
samples in the multidimensional space. (PPTX 140 kb)
Additional file 12: Conservation scores calculated with the phastCons
alignment algorithm for 100 vertebrate species over the UCSC hg19
genome. Only exonic regions were used in the calculation. (XLSX 30 kb)
Additional file 13: Gene coexpression network derived from the
expression values of the 489 genes along the exon arrays in 15 samples
of the different cell types studied. The coexpression was calculated using
a Pearson correlation with a stringent cutoff to select the pairs with
correlation coefficient r≥ 0.95, allowing the selection of the best gene
pairs. In this analysis the genes that correspond to known CD markers
(CDs) and to transcription factors (TFs) are highlighted to illustrate
possible interesting links. (PPTX 1551 kb)
Additional file 14: Cytoscape file (produced with Cytoscape version
3.1.0) that includes a gene coexpression network derived from the
expression values of the 489 genes along the exon arrays in 15 samples
of the different cell types studied. The coexpression was calculated using
a Pearson correlation with a stringent cutoff to select the pairs with
correlation coefficient r≥ 0.95. The file includes only the gene pairs that
passed the cutoff threshold, incorporating 447 genes and 9969
interactions. Several views of the network are included and various
clusters of genes were produced as subnetworks. Biological information
and annotation for individual genes is also provided. (CYS 781 kb)
Additional file 15: Functional enrichment analysis of the genes
corresponding to the sets that are found overexpressed in the contrasts
of each tissue-MSC subtype versus other mesenchymal/stromal subtypes.
These gene lists are: 281 genes for AD-MSCs, and 412 genes for BM-MSCs
and 531 genes for PL-MSCs. The file includes three tables with the data
obtained with the DAVID functional enrichment tool. Each table includes
the most relevant functional terms with significant p-values. (XLSX 68 kb)
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